MiniVax
MiniVax is focused on the development of solutions for the treatment and prevention of opportunistic infections.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | $110k | Seed | |
| Total Funding | 000k | ||
Related Content
MiniVax Corp is a biotechnology company specializing in the development of vaccines and immunotherapies aimed at combating infectious diseases. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies. Operating in the global biotech market, MiniVax Corp employs a business model centered around research and development, clinical trials, and partnerships with larger pharmaceutical firms. Revenue is generated through licensing agreements, government grants, and milestone payments from collaborative projects. The company's core focus is on leveraging advanced biotechnological methods to create effective and safe medical solutions for widespread health challenges.
Keywords: biotechnology, vaccines, immunotherapy, infectious diseases, healthcare, research, development, clinical trials, licensing, partnerships.